<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01072695</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-196-0112</org_study_id>
    <nct_id>NCT01072695</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of GS-9256 and GS-9190 Alone and in Combination With Ribavirin for 28 Days in Patients With Chronic Hepatitis C Virus Infection</brief_title>
  <official_title>A Phase 2, Randomized, Open-Label Trial of GS-9256 Plus GS-9190 Alone and in Combination With Ribavirin for 28 Days in Treatment Naïve Subjects With Chronic Genotype 1 Hepatitis C Virus Infection (Protocol No. GS-US-196-0112)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This a phase 2, randomized, open-label trial of GS-9256 plus GS-9190, two oral anti HCV
      drugs, for 28 days with and without ribavirin (RIBA) and with pegylated interferon (PEG)/RIBA
      in adults with chronic Hepatitis C virus (HCV). In Part A, approximately thirty (30) subjects
      18-70 years of age who meet study entry criteria will be randomized (in other words, selected
      at random, like flipping a coin) to one of the two treatment groups (GS-9256 plus GS-9190 or
      GS-9256 plus GS-9190 plus RIBA). In Part B, an additional fifteen (15) subjects will receive
      75 mg GS-9256 BID plus 40 mg GS-9190 BID in combination with PEG/RIBA. After the 28-day
      treatment period, subjects will receive PEG/RIBA as standard of care (SOC).

      Following randomization, subjects will return for a Baseline (Day 1) visit, at which time
      study medication will be dispensed and subjects will enter a 28 day treatment phase. During
      the treatment phase, subjects will receive oral study drugs twice daily for 28 days and PEG
      once weekly for Part B. Subjects then receive PEG/RIBA as local SOC starting on Day 28 (not
      provided as part of the study). Following completion of the 28-day treatment phase, subjects
      will be followed for approximately 72 weeks.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      GS-9256 (an HCV NS3 protease inhibitor) plus GS-9190 (non-nucleoside HCV NS5B inhibitor) will
      be administered for 28 days with and without RIBA (weight-based dosing) and with PEG/RIBA in
      treatment-naïve subjects with chronic genotype 1 HCV infection. In Part A, thirty (30)
      subjects with genotype 1 will be randomized to 75 mg GS-9256 BID plus 40 mg GS-9190 BID or 75
      mg GS-9256 BID plus 40 mg GS-9190 BID plus RIBA 1000-1200 mg/day for 28 days. In Part B, an
      additional fifteen (15) subjects with genotype 1 will receive 75 mg GS-9256 BID plus 40 mg
      GS-9190 BID in combination with PEG/RIBA for 28 days. After the 28-day treatment period,
      subjects will receive PEG/RIBA as standard of care (SOC).

      In Part A, for any subjects meeting pre-defined, individual, virologic criteria, PEG/RIBA
      standard of care will be started prior to Day 28.

      Both PEG and RIBA will be administered at their currently approved dosages for treatment of
      HCV infection in accordance with appropriate labeling. Subjects will be monitored for safety
      (including ECG monitoring), antiviral activity, pharmacokinetics, and resistance 2-3 times
      weekly through Day 28.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of subjects achieving rapid virologic response (RVR)</measure>
    <time_frame>Day 28</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AEs, physical examination and clinical laboratory test findings, vital signs, ECGs</measure>
    <time_frame>Throughout first six weeks of study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma pharmacokinetics</measure>
    <time_frame>Throughout Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Viral resistance</measure>
    <time_frame>Throughout study</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>HCV Infection</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GS-9256</intervention_name>
    <description>75 mg BID x 28 days</description>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_label>Arm 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GS-9190</intervention_name>
    <description>40 mg BID x 28 days</description>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_label>Arm 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin</intervention_name>
    <description>1000-1200 mg/day given BID</description>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_label>Arm 3</arm_group_label>
    <other_name>COPEGUS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Peginterferon alfa-2a</intervention_name>
    <description>180 ug q week</description>
    <arm_group_label>Arm 3</arm_group_label>
    <other_name>Pegasys</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult subjects, ages 18-70

          -  Willing able to provide informed consent

          -  BMI between 18 and 36 kg/m2 (inclusive)

          -  Chronic HCV infection, genotype 1

          -  HCV RNA &gt;/= 3 log, but &lt; 7.2 log10 IU/ml at screen

          -  Liver biopsy, FibroTest, or FibroScan indicating absence of cirrhosis

          -  HCV treatment naïve with imminent plans to start treatment with PEG/RIBA

          -  QTcF &lt;/= 450 msec at screen

          -  ALT, AST, GGT &lt; 5 X ULN at the screening visit

          -  Creatinine clearance &gt;= 50 mL/min

          -  Absolute neutrophil count &gt;= 1500/mm3

          -  Hemoglobin &gt;/= 12 g/dL (female), &gt;/= 13 g/dL (male)

          -  Males agree to use of effective contraception and refrain from sperm donation

          -  Able to comply with dosing instructions and study visits

          -  Of generally good health

        Exclusion Criteria:

          -  Females of child-bearing potential or males with female partners who are pregnant or
             planning to become pregnant

          -  Infection with other HCV genotype or multiple HCV genotypes

          -  Poorly controlled diabetes

          -  Hemoglobinopathy or known retinal disease

          -  History of sarcoidosis or invasive malignancy

          -  Untreated or significant psychiatric illness

          -  Co-infection with hepatitis B virus or human immunodeficiency virus

          -  Chronic use of systemic immunosuppressive agents

          -  Autoimmune disorders

          -  Severe COPD

          -  History of significant cardiac disease

          -  Known cirrhosis

          -  Non-HCV chronic liver disease

          -  Transplantation

          -  Suspicion of hepatocellular carcinoma

          -  Bilirubin above the normal range or Gilbert's syndrome

          -  Decompensated liver disease

          -  Clinically significant illness

          -  GI disease that could interfere with absorption

          -  Acute porphyria

          -  Current excessive alcohol ingestion, averaging &gt; 3 drinks/day for females and &gt; 4
             drinks/day for males or current binge drinking

          -  Positive urine drug screen

          -  History of difficult blood collection

          -  Significant recent blood loss

          -  Prohibited medications, including H2 antagonists, investigational agents

          -  Restricted fruits, fruit juices

          -  Hypersensitivity
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juan Betular</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bruxelles</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Clichy</city>
        <zip>92110</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>La Tronche</city>
        <zip>38700</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Duesseldorf</city>
        <zip>40237</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamburg</city>
        <zip>20099</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wurzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <zip>E1 2AT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 19, 2010</study_first_submitted>
  <study_first_submitted_qc>February 19, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 22, 2010</study_first_posted>
  <last_update_submitted>May 30, 2012</last_update_submitted>
  <last_update_submitted_qc>May 30, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 31, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatitis C</keyword>
  <keyword>HCV</keyword>
  <keyword>GS-9256</keyword>
  <keyword>GS-9190</keyword>
  <keyword>Genotype 1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Peginterferon alfa-2a</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

